Many of you have been following the redevelopment and reintroduction of the powerful and effective OSR#1 supplement that we used to recommend for metal chelation and as a antioxidant. The development and FDA approval of the product from a supplement to an official medical product has progressed enough that it now has an official new name.
Ermes Medical Company Limited (formerly CTI Science) is pleased to announce that it has taken the name EmeraMed Limited. The new name will allow for closer identification with its product.
NBMI (formally OSR#1) has been assigned an international Non-proprietary Name (generic name) Emeramide. The drug trade name, Irminix, has also been approved by the European Medicines Agency. On the drug packages in the pharmacy all three name will appear – Irminix, Emeramide, and EmeraMed.
Along with its new name, EmeraMed has launched a new website, www.emeramed.com. Please browse the site for content and check back frequently for updates on the official grand reintroduction.
Phase 2a clinical efficacy trials are continuing in Ecuador and are going well. We expect the study to be completed before Christmas with the analysis ready by February 2016. Also, the first Named Patient Use/Individual Patient IND treatments have started, indicating that there is a need for this drug.
Thank you for your support and stay tuned for updates.